|
|
Volumn 24, Issue 4, 2006, Pages 373-374
|
|
Hedge funds gain edge by doubling biotech investments
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
PARATHYROID HORMONE;
VACCINE;
BIOTECHNOLOGY;
COMPARATIVE STUDY;
COST BENEFIT ANALYSIS;
DRUG COST;
DRUG INDUSTRY;
DRUG MARKETING;
FINANCIAL MANAGEMENT;
FUNDING;
GOVERNMENT;
HEALTH CARE;
HEALTH CARE COST;
HUMAN;
INVESTMENT;
NOTE;
OSTEOPOROSIS;
PRIORITY JOURNAL;
PROFIT;
BIOTECHNOLOGY;
CAPITAL FINANCING;
INVESTMENTS;
OWNERSHIP;
UNITED STATES;
|
|
EID: 33645750051
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0406-373 Document Type: Note |
|
Times cited : (1)
|
|
References (0)
|
